Celltrion’s biosimilar ‘Herzuma’ proven in equivalence of efficacy with original

Published: 2017-09-13 16:27:00
Updated: 2017-09-13 11:04:15

At the European Society for Medical Oncology(ESMO) symposium on the 9th(local time) in Madrid, Spain, Celltrion announced additional clinical trial results of 1-year safety of Herzuma(development name: CT-P6), an antibody biosimilar for the treatment of breast cancer, on early breast cancer patie...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.